AR027748A1 - Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma - Google Patents
Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la mismaInfo
- Publication number
- AR027748A1 AR027748A1 ARP010101516A ARP010101516A AR027748A1 AR 027748 A1 AR027748 A1 AR 027748A1 AR P010101516 A ARP010101516 A AR P010101516A AR P010101516 A ARP010101516 A AR P010101516A AR 027748 A1 AR027748 A1 AR 027748A1
- Authority
- AR
- Argentina
- Prior art keywords
- globules
- small spheres
- stavudine
- spheres
- extrusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan formas de dosificacion prolongada de estavudina que comprenden pequenas esferas o globulos formados por extrusion-formacion de pequenasesferas o globulos y recubiertos con un recubrimiento de sellado. Las pequenas esferas o globulos s e recubren también con un recubrimiento de liberacionmodificada de modo que una cápsula de gelatina rígida que contiene tales pequenas esferas o globulos proporcionará niveles en sangra de estavudina duranteaproximadamente 24 horas. Las pequenas esfe ras o globulos se preparan de una mezcla seca de estavudina, un agente formador de pequenas esferas o globulos, undiluyente adecuado y una cantidad estabilizadora de estearato de magnesio. El estearato de magnesio, en contraste con otros aditivos far macéuticos similares,se encontro que estabiliza a la estavudina contra la degradacion debido a hidrolisis en presencia de la cantidad limitada de agua necesaria para el proceso deextrusion-formacion de pequenas esferas o globulos. También se incluye en el alcance de la presente cápsulas de gelatina rígida que contienen, además de laspequenas esferas o globulos de estavudina, pequenas esferas o globulos similares que contienen otros agentes terapéuticos utilizados para tratar infeccionesretrovira les.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19358800P | 2000-03-30 | 2000-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027748A1 true AR027748A1 (es) | 2003-04-09 |
Family
ID=22714247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101516A AR027748A1 (es) | 2000-03-30 | 2001-03-29 | Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma |
Country Status (26)
Country | Link |
---|---|
US (1) | US7135465B2 (es) |
EP (1) | EP1267879A2 (es) |
JP (1) | JP2003528905A (es) |
KR (1) | KR20030011805A (es) |
CN (1) | CN1187052C (es) |
AR (1) | AR027748A1 (es) |
AU (1) | AU2001249591A1 (es) |
BG (1) | BG107157A (es) |
BR (1) | BR0109602A (es) |
CA (1) | CA2404687A1 (es) |
CZ (1) | CZ20023003A3 (es) |
EE (1) | EE200200564A (es) |
GE (1) | GEP20043285B (es) |
HU (1) | HUP0302631A2 (es) |
IL (1) | IL151475A0 (es) |
LT (1) | LT5045B (es) |
LV (1) | LV12939B (es) |
MX (1) | MXPA02009534A (es) |
NO (1) | NO20024645L (es) |
NZ (1) | NZ522250A (es) |
PE (1) | PE20011179A1 (es) |
PL (1) | PL366089A1 (es) |
RU (1) | RU2239435C2 (es) |
SK (1) | SK12822002A3 (es) |
WO (1) | WO2001074329A2 (es) |
ZA (1) | ZA200207760B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
KR20050047507A (ko) * | 2002-06-27 | 2005-05-20 | 시락 아게 | 구형 펠렛 제제 |
US8802139B2 (en) * | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN100548309C (zh) * | 2004-11-24 | 2009-10-14 | 东北制药总厂 | 司他夫定缓释片剂 |
TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
EP1898890A1 (en) * | 2005-06-16 | 2008-03-19 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
US20080241265A1 (en) * | 2005-08-31 | 2008-10-02 | Amar Lulla | Pharmaceutical Combinations Containing Lamivudine, Stavudine and Nevirapine |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CA2648280C (en) * | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
EP2010162A4 (en) * | 2006-04-03 | 2013-01-09 | Isa Odidi | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
CN102319181B (zh) * | 2011-09-08 | 2014-07-16 | 广东大华农动物保健品股份有限公司 | 一种微囊型动物药品的包被工艺 |
US20140271893A1 (en) * | 2013-03-15 | 2014-09-18 | Mcneil-Ppc, Inc. | Coated phenylephrine particles and use thereof in pharmaceutical formulations |
BR112017000295A2 (pt) * | 2014-07-17 | 2017-11-07 | Dow Global Technologies Llc | dispersão e película de etilcelulose |
CN105511174A (zh) * | 2016-01-05 | 2016-04-20 | 深圳市华星光电技术有限公司 | 液晶显示面板和显示装置 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4671963A (en) * | 1983-10-28 | 1987-06-09 | Germino Felix J | Stearate treated food products |
US4670270A (en) * | 1984-05-07 | 1987-06-02 | Germino Felix J | Stearate treated food products |
US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US4978655A (en) * | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
GB8707421D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
EP0619731B1 (en) | 1991-12-30 | 2000-10-04 | Fmc Corporation | Microcrystalline cellulose spheronization composition |
US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
FI101039B (fi) | 1992-10-09 | 1998-04-15 | Eeva Kristoffersson | Menetelmä lääkepellettien valmistamiseksi |
US5869097A (en) * | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
GB9403449D0 (en) | 1994-02-23 | 1994-04-13 | Wellcome Found | Therapeutic benzonitriles |
JPH10500938A (ja) | 1994-03-07 | 1998-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラチルプロテアーゼインヒビターとしてのスルホンアミド誘導体 |
KR19980701739A (ko) | 1995-02-23 | 1998-06-25 | 디르크 반테 | 신경보호제로서 융합된 벤조티아졸의 용도 |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
PL327199A1 (en) | 1995-12-15 | 1998-11-23 | Cryopreservation Tech Cc | Composition for cryopreservation of body organs and for treating viral and bacterial infections |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US5883252A (en) | 1996-01-26 | 1999-03-16 | Vertex Pharmaceuticals Incorporated | Aspartyl protease inhibitors |
US5766623A (en) * | 1996-03-25 | 1998-06-16 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Compactable self-sealing drug delivery agents |
US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
US5905068A (en) | 1996-09-24 | 1999-05-18 | Abbott Laboratories | Retroviral protease inhibiting compounds |
DE69735002T2 (de) | 1996-10-25 | 2006-10-26 | Shire Laboratories, Inc. | Osmotisches Verabreichungssystem für lösliche Dosen |
US5962462A (en) | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US5919776A (en) | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
JP2002522354A (ja) * | 1997-09-19 | 2002-07-23 | シャイア ラボラトリーズ,インコーポレイテッド | 固溶体ビードレット |
US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
US6013644A (en) | 1997-12-12 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n-酰苯胺衍生物的药物组合物 |
US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US6093743A (en) | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
MXPA00012842A (es) | 1998-06-24 | 2004-06-22 | Univ Emory | Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih. |
EP1165077B1 (en) | 1999-03-31 | 2005-06-29 | UAF Technologies and Research, LLC | Viral treatment |
US6136835A (en) | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
-
2001
- 2001-03-29 AU AU2001249591A patent/AU2001249591A1/en not_active Abandoned
- 2001-03-29 EE EEP200200564A patent/EE200200564A/xx unknown
- 2001-03-29 GE GEAP20016630A patent/GEP20043285B/en unknown
- 2001-03-29 SK SK1282-2002A patent/SK12822002A3/sk unknown
- 2001-03-29 EP EP01922832A patent/EP1267879A2/en not_active Withdrawn
- 2001-03-29 MX MXPA02009534A patent/MXPA02009534A/es not_active Application Discontinuation
- 2001-03-29 KR KR1020027012769A patent/KR20030011805A/ko not_active Application Discontinuation
- 2001-03-29 IL IL15147501A patent/IL151475A0/xx unknown
- 2001-03-29 CA CA002404687A patent/CA2404687A1/en not_active Abandoned
- 2001-03-29 WO PCT/US2001/010078 patent/WO2001074329A2/en not_active Application Discontinuation
- 2001-03-29 RU RU2002126540/15A patent/RU2239435C2/ru not_active IP Right Cessation
- 2001-03-29 AR ARP010101516A patent/AR027748A1/es unknown
- 2001-03-29 PL PL01366089A patent/PL366089A1/xx not_active Application Discontinuation
- 2001-03-29 US US09/821,103 patent/US7135465B2/en not_active Expired - Lifetime
- 2001-03-29 HU HU0302631A patent/HUP0302631A2/hu unknown
- 2001-03-29 CZ CZ20023003A patent/CZ20023003A3/cs unknown
- 2001-03-29 NZ NZ522250A patent/NZ522250A/en unknown
- 2001-03-29 JP JP2001572074A patent/JP2003528905A/ja active Pending
- 2001-03-29 CN CNB018074405A patent/CN1187052C/zh not_active Expired - Fee Related
- 2001-03-29 BR BR0109602-8A patent/BR0109602A/pt not_active IP Right Cessation
- 2001-03-30 PE PE2001000297A patent/PE20011179A1/es not_active Application Discontinuation
-
2002
- 2002-09-06 LT LT2002099A patent/LT5045B/lt not_active IP Right Cessation
- 2002-09-26 ZA ZA200207760A patent/ZA200207760B/en unknown
- 2002-09-27 NO NO20024645A patent/NO20024645L/no not_active Application Discontinuation
- 2002-09-30 BG BG107157A patent/BG107157A/xx unknown
- 2002-10-25 LV LVP-02-187A patent/LV12939B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2002126540A (ru) | 2004-03-27 |
EP1267879A2 (en) | 2003-01-02 |
MXPA02009534A (es) | 2003-05-14 |
PE20011179A1 (es) | 2001-12-06 |
WO2001074329A2 (en) | 2001-10-11 |
LT2002099A (en) | 2003-04-25 |
PL366089A1 (en) | 2005-01-24 |
US20020002147A1 (en) | 2002-01-03 |
CN1187052C (zh) | 2005-02-02 |
LV12939B (en) | 2003-04-20 |
NO20024645D0 (no) | 2002-09-27 |
KR20030011805A (ko) | 2003-02-11 |
BR0109602A (pt) | 2004-06-29 |
ZA200207760B (en) | 2004-01-30 |
CZ20023003A3 (cs) | 2002-11-13 |
BG107157A (en) | 2003-06-30 |
JP2003528905A (ja) | 2003-09-30 |
RU2239435C2 (ru) | 2004-11-10 |
CA2404687A1 (en) | 2001-10-11 |
IL151475A0 (en) | 2003-04-10 |
LT5045B (lt) | 2003-08-25 |
AU2001249591A1 (en) | 2001-10-15 |
US7135465B2 (en) | 2006-11-14 |
NO20024645L (no) | 2002-09-27 |
NZ522250A (en) | 2004-09-24 |
HUP0302631A2 (hu) | 2003-11-28 |
EE200200564A (et) | 2004-06-15 |
WO2001074329A3 (en) | 2002-05-10 |
CN1420774A (zh) | 2003-05-28 |
SK12822002A3 (sk) | 2003-02-04 |
GEP20043285B (en) | 2004-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR027748A1 (es) | Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma | |
BRPI0409345A (pt) | sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo | |
NO971965L (no) | Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
BR0211317A (pt) | Sistema para a liberação controlada de uma droga por meio de retenção gástrica | |
ES2118677T3 (es) | Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. | |
ES2185758T3 (es) | Utilizacion de esteres grasos etoxilados como compuestos auto-emulsionables. | |
CO5150202A1 (es) | Composicion de tisu facial y metodo para usarla para el secuestro de irritantes de la piel de la secrecion nasal | |
UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
BR0210267A (pt) | Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases | |
AR002266A1 (es) | Composicion farmaceutica de gelatina blanda o forma de dosis que la incluye | |
BR9906372A (pt) | Composição farmaceutica aquosa para aplicação na mucosa | |
BR0116945A (pt) | Uma preparação para prevenção de restenose | |
ATE227136T1 (de) | Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon | |
BR0212975A (pt) | Elemento de liberação de dosagem controlada, e, métodos para a liberação de pelo menos um primeiro agente ativo para dentro do rúmen de um animal ruminante, para o tratamento, a profilaxia ou ambos de um estado infestado ou doentio em um animal ruminante e para a alteração do estado fisiológico de um animal ruminante | |
KR900701261A (ko) | 비만증 치료방법 | |
AR019622A1 (es) | Composicion dentifrica que contiene ingredientes reactivos encapsulados y un metodo para aplicar ajustes terapeuticos a los dientes utilizando dichacomposicion | |
ES2059495T3 (es) | Dispositivo de descarga de farmacos regulado por solubilidad. | |
GB1484972A (en) | Method of sterilising medical and surgical instruments | |
BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida | |
PE84399A1 (es) | Formas de dosificacion de sertralina de liberacion retardada | |
BRPI0510694A (pt) | composições farmacêuticas compreendendo ingredientes ativos concentrados encapsuladas em gelatina mole | |
ES2180729T3 (es) | Tratamiento terapeutico combinado de las patologias hiperproliferantes. | |
PA8542501A1 (es) | Composicion | |
KR920014474A (ko) | 담석 붕괴용 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |